Cargando…

Characterization of the Maternally Derived Antibody Immunity against Rhdv-2 after Administration in Breeding Does of an Inactivated Vaccine

Inactivated strain-specific vaccines have been successfully used to control rabbit haemorrhagic disease (RHD) caused by RHDV-2 in the rabbit industry. It is unknown whether and how vaccination of breeding does contributed to protect the population of young susceptible rabbit kits. The present study...

Descripción completa

Detalles Bibliográficos
Autores principales: Baratelli, Massimiliano, Molist-Badiola, Joan, Puigredon-Fontanet, Alba, Pascual, Mariam, Boix, Oriol, Mora-Igual, Francesc Xavier, Woodward, Michelle, Lavazza, Antonio, Capucci, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564433/
https://www.ncbi.nlm.nih.gov/pubmed/32872139
http://dx.doi.org/10.3390/vaccines8030484
_version_ 1783595713709473792
author Baratelli, Massimiliano
Molist-Badiola, Joan
Puigredon-Fontanet, Alba
Pascual, Mariam
Boix, Oriol
Mora-Igual, Francesc Xavier
Woodward, Michelle
Lavazza, Antonio
Capucci, Lorenzo
author_facet Baratelli, Massimiliano
Molist-Badiola, Joan
Puigredon-Fontanet, Alba
Pascual, Mariam
Boix, Oriol
Mora-Igual, Francesc Xavier
Woodward, Michelle
Lavazza, Antonio
Capucci, Lorenzo
author_sort Baratelli, Massimiliano
collection PubMed
description Inactivated strain-specific vaccines have been successfully used to control rabbit haemorrhagic disease (RHD) caused by RHDV-2 in the rabbit industry. It is unknown whether and how vaccination of breeding does contributed to protect the population of young susceptible rabbit kits. The present study investigates whether the immunity against RHDV-2 produced by vaccination of breeding does is transmitted to their progeny and its dynamic once inherited by kits. For this purpose, New Zealand female rabbits of 8–9 weeks of age were allocated into 2 groups of 40 subjects each and bred during 6 reproductive cycles. The first experimental group was vaccinated with a commercially available inactivated vaccine against RHDV-2 whereas the second group was inoculated with PBS. Moreover, the present study was also meant to identify the mechanisms of transmission of that maternal immunity. For this reason, rabbit kits of vaccinated and non-vaccinated breeding does were cross-fostered before milk uptake. The RHDV-2 antibody response was monitored in the blood serum of breeding does and of their kits by competition ELISA (cELISA) and solid-phase ELISA (spELISA). Since it has been clearly demonstrated that cELISA positive rabbits are protected from RHD, we avoided the resorting of the challenge of the kits with RHDV-2. Results showed that RHDV-2 antibodies were inherited by kits up to one year from vaccination of breeding does. Once inherited, the maternally derived antibody response against RHDV-2 lasted at least until 28 days of life. Finally, the study also elucidated that the major contribution to the maternal derived immunity against RHDV-2 in kits was provided during gestation and probably transmitted through transplacental mechanisms although lactation provided a little contribution to it. The present study contributed to elucidate the characteristics of the maternal antibody immunity produced by vaccination and its mechanisms of transmission.
format Online
Article
Text
id pubmed-7564433
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75644332020-10-26 Characterization of the Maternally Derived Antibody Immunity against Rhdv-2 after Administration in Breeding Does of an Inactivated Vaccine Baratelli, Massimiliano Molist-Badiola, Joan Puigredon-Fontanet, Alba Pascual, Mariam Boix, Oriol Mora-Igual, Francesc Xavier Woodward, Michelle Lavazza, Antonio Capucci, Lorenzo Vaccines (Basel) Article Inactivated strain-specific vaccines have been successfully used to control rabbit haemorrhagic disease (RHD) caused by RHDV-2 in the rabbit industry. It is unknown whether and how vaccination of breeding does contributed to protect the population of young susceptible rabbit kits. The present study investigates whether the immunity against RHDV-2 produced by vaccination of breeding does is transmitted to their progeny and its dynamic once inherited by kits. For this purpose, New Zealand female rabbits of 8–9 weeks of age were allocated into 2 groups of 40 subjects each and bred during 6 reproductive cycles. The first experimental group was vaccinated with a commercially available inactivated vaccine against RHDV-2 whereas the second group was inoculated with PBS. Moreover, the present study was also meant to identify the mechanisms of transmission of that maternal immunity. For this reason, rabbit kits of vaccinated and non-vaccinated breeding does were cross-fostered before milk uptake. The RHDV-2 antibody response was monitored in the blood serum of breeding does and of their kits by competition ELISA (cELISA) and solid-phase ELISA (spELISA). Since it has been clearly demonstrated that cELISA positive rabbits are protected from RHD, we avoided the resorting of the challenge of the kits with RHDV-2. Results showed that RHDV-2 antibodies were inherited by kits up to one year from vaccination of breeding does. Once inherited, the maternally derived antibody response against RHDV-2 lasted at least until 28 days of life. Finally, the study also elucidated that the major contribution to the maternal derived immunity against RHDV-2 in kits was provided during gestation and probably transmitted through transplacental mechanisms although lactation provided a little contribution to it. The present study contributed to elucidate the characteristics of the maternal antibody immunity produced by vaccination and its mechanisms of transmission. MDPI 2020-08-28 /pmc/articles/PMC7564433/ /pubmed/32872139 http://dx.doi.org/10.3390/vaccines8030484 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Baratelli, Massimiliano
Molist-Badiola, Joan
Puigredon-Fontanet, Alba
Pascual, Mariam
Boix, Oriol
Mora-Igual, Francesc Xavier
Woodward, Michelle
Lavazza, Antonio
Capucci, Lorenzo
Characterization of the Maternally Derived Antibody Immunity against Rhdv-2 after Administration in Breeding Does of an Inactivated Vaccine
title Characterization of the Maternally Derived Antibody Immunity against Rhdv-2 after Administration in Breeding Does of an Inactivated Vaccine
title_full Characterization of the Maternally Derived Antibody Immunity against Rhdv-2 after Administration in Breeding Does of an Inactivated Vaccine
title_fullStr Characterization of the Maternally Derived Antibody Immunity against Rhdv-2 after Administration in Breeding Does of an Inactivated Vaccine
title_full_unstemmed Characterization of the Maternally Derived Antibody Immunity against Rhdv-2 after Administration in Breeding Does of an Inactivated Vaccine
title_short Characterization of the Maternally Derived Antibody Immunity against Rhdv-2 after Administration in Breeding Does of an Inactivated Vaccine
title_sort characterization of the maternally derived antibody immunity against rhdv-2 after administration in breeding does of an inactivated vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564433/
https://www.ncbi.nlm.nih.gov/pubmed/32872139
http://dx.doi.org/10.3390/vaccines8030484
work_keys_str_mv AT baratellimassimiliano characterizationofthematernallyderivedantibodyimmunityagainstrhdv2afteradministrationinbreedingdoesofaninactivatedvaccine
AT molistbadiolajoan characterizationofthematernallyderivedantibodyimmunityagainstrhdv2afteradministrationinbreedingdoesofaninactivatedvaccine
AT puigredonfontanetalba characterizationofthematernallyderivedantibodyimmunityagainstrhdv2afteradministrationinbreedingdoesofaninactivatedvaccine
AT pascualmariam characterizationofthematernallyderivedantibodyimmunityagainstrhdv2afteradministrationinbreedingdoesofaninactivatedvaccine
AT boixoriol characterizationofthematernallyderivedantibodyimmunityagainstrhdv2afteradministrationinbreedingdoesofaninactivatedvaccine
AT moraigualfrancescxavier characterizationofthematernallyderivedantibodyimmunityagainstrhdv2afteradministrationinbreedingdoesofaninactivatedvaccine
AT woodwardmichelle characterizationofthematernallyderivedantibodyimmunityagainstrhdv2afteradministrationinbreedingdoesofaninactivatedvaccine
AT lavazzaantonio characterizationofthematernallyderivedantibodyimmunityagainstrhdv2afteradministrationinbreedingdoesofaninactivatedvaccine
AT capuccilorenzo characterizationofthematernallyderivedantibodyimmunityagainstrhdv2afteradministrationinbreedingdoesofaninactivatedvaccine